Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Aromasin "Suicide Inhibition" May Distinguish Drug From Other Inhibitors

  • News

Executive Summary

Aromasin's labeled "suicide inhibition" mechanism of action could be used by Pharmacia & Upjohn to distinguish the new drug, approved Oct. 21, from nonsteroidal aromatase inhibitors in the treatment of breast cancer.

You may also be interested in...



Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal

Searle will create a platform for new oncologics development through a research collaboration with Cambridge Antibody Technology.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
Latest Headlines

Cell/Gene Therapy Is Ripe For Real-World Data Given Length Of Follow-Up Required, Abernethy Says

China May Ease Data Transfer Rules But Regulatory Ambiguity Remains

Amgen’s Lumakras: FDA Flags ‘Marginal’ Efficacy Results, Potential Systemic Bias In Lung Cancer Trial

Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake

See All
UsernamePublicRestriction

Register

PS035071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By